Pavan Reddy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pavan Reddy has a total of 533 co-authors. Here are the top co-authors by number of shared publications:
Yaping Sun
Baylor College of Medicine
38 shared publicationsKatherine Oravecz-Wilson
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
24 shared publicationsChen Liu
Department of Pathology and Laboratory Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
19 shared publicationsTomomi Toubai
Department of Internal Medicine, Michigan Medicine, Ann Arbor, USA
18 shared publicationsHideaki Fujiwara
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI, USA
17 shared publications- Nathan D. Mathewson
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
14 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Springer Nature in Research Square
Dio2+Il11+ fibroblasts constitute a local stromal-endocrine niche that promotes intestinal stem cell regeneration after immune-mediated injury
Immune-mediated damage depletes intestinal stem cells (ISCs) and their homeostatic niche. Whether inflammatory injury induces an alternative niche that promotes regeneration remains unknown. Using single-cell spatial transcriptomics in murine gastrointestinal graft-versus-host disease, we identified cytotoxic CD8⁺ T cells accumulated near intestinal crypts coinciding with ISC, Paneth cell depletion, and epithelial death pathway activation. A distinct Dio2⁺ Il11⁺ fibroblast population emerged in regions of maximal intestinal damage between the epithelial progenitors and stromal cells. These fibroblasts expressed cAMP-response and immune-recruitment programs, suggesting niche reorganization. Thyroid hormone receptor antagonism reduced organoid budding, whereas enhancing thyroid hormone signaling promoted morphogenesis, particularly with IL-11, linking local T3 and IL-11 secretion by these Dio2⁺ Il11⁺ cells to ISC regeneration. Similar niches were observed in DSS-induced colitis model and in biopsies from patients with Crohn’s disease. Our data identify Dio2⁺ Il11⁺ fibroblasts as a stromal-endocrine niche at the site of immune injury that supports ISC regeneration.
- 16 October 2026
- Published by Springer Nature in Research Square
Open AccessDio2+Il11+ fibroblasts constitute a local stromal-endocrine niche that promotes intestinal stem cell regeneration after immune-mediated injury
Immune-mediated damage depletes intestinal stem cells (ISCs) and their homeostatic niche. Whether inflammatory injury induces an alternative niche that promotes regeneration remains unknown. Using single-cell spatial transcriptomics in murine gastrointestinal graft-versus-host disease, we identified cytotoxic CD8⁺ T cells accumulated near intestinal crypts coinciding with ISC, Paneth cell depletion, and epithelial death pathway activation. A distinct Dio2⁺ Il11⁺ fibroblast population emerged in regions of maximal intestinal damage between the epithelial progenitors and stromal cells. These fibroblasts expressed cAMP-response and immune-recruitment programs, suggesting niche reorganization. Thyroid hormone receptor antagonism reduced organoid budding, whereas enhancing thyroid hormone signaling promoted morphogenesis, particularly with IL-11, linking local T3 and IL-11 secretion by these Dio2⁺ Il11⁺ cells to ISC regeneration. Similar niches were observed in DSS-induced colitis model and in biopsies from patients with Crohn’s disease. Our data identify Dio2⁺ Il11⁺ fibroblasts as a stromal-endocrine niche at the site of immune injury that supports ISC regeneration.
- Open Access
- 24 September 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (21)
Vorinostat for graft-versus-host disease prevention in pediatric and young adult patients with hematologic malignancies
BACKGROUND: This prospective, single-arm, multicenter phase I/II trial evaluated vorinostat added to standard graft-versus-host disease (GVHD) prophylaxis in pediatric, adolescent, and young adult (AYA) patients undergoing allogeneic hematopoietic cell transplantation (HCT) from HLA-matched related, HLA-matched unrelated, and haploidentical donors. METHODS: Patients aged 3–39 years received twice-daily vorinostat with tacrolimus/methotrexate after HLA-matched HCT from day –10 to +30, or with posttransplant cyclophosphamide/tacrolimus/mycophenolate mofetil after haploidentical HCT from day +5 to +30. The primary endpoint was cumulative incidence of grade 2–4 acute GVHD by day +100. All outcomes were based on intention-to-treat analysis. RESULTS: Forty-three patients were enrolled; median age was 19 years, with 74% receiving HLA-matched and 26% haploidentical HCT. The recommended phase II dose was 60 mg/m 2 twice daily. No dose-limiting toxicities, unexpected vorinostat-related serious adverse events, or primary graft failures occurred. Median neutrophil and platelet recovery occurred at 14 and 18 days, respectively. Day +100 grade 2–4 and 3–4 acute GVHD were 14% (95% CI, 5.6%–26%) and 4.7% (95% CI, 0.83%–14%), respectively. One-year overall survival was 88.4% (95% CI, 79.3%–98.5%), relapse 14% (95% CI, 5.6%–26%), nonrelapse mortality 4.7% (95% CI, 0.8%–14%), and GVHD-free/relapse-free survival 55.8% (95% CI, 42.8%–72.8%). Correlative studies demonstrated on-target HDAC activity, with increased histone. RESULTS: Forty-three patients were enrolled; median age was 19 years, with 74% receiving HLA-matched and 26% haploidentical HCT. The recommended phase II dose was 60 mg/m 2 twice daily. No dose-limiting toxicities, unexpected vorinostat-related serious adverse events, or primary graft failures occurred. Median neutrophil and platelet recovery occurred at 14 and 18 acetylation and lower proinflammatory cytokines. CONCLUSION: These findings support randomized evaluation of vorinostat-based GVHD prophylaxis in pediatric and AYA HCT. TRIAL REGISTRY: ClinicalTrials.gov NCT03842696. FUNDING: NIH grants 1R01CA249211, UG1HL069330, 1K24HL156896, and NHLBI Training Grant T32HL007622-36.
- 24 September 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (21)
Open AccessVorinostat for graft-versus-host disease prevention in pediatric and young adult patients with hematologic malignancies
BACKGROUND: This prospective, single-arm, multicenter phase I/II trial evaluated vorinostat added to standard graft-versus-host disease (GVHD) prophylaxis in pediatric, adolescent, and young adult (AYA) patients undergoing allogeneic hematopoietic cell transplantation (HCT) from HLA-matched related, HLA-matched unrelated, and haploidentical donors. METHODS: Patients aged 3–39 years received twice-daily vorinostat with tacrolimus/methotrexate after HLA-matched HCT from day –10 to +30, or with posttransplant cyclophosphamide/tacrolimus/mycophenolate mofetil after haploidentical HCT from day +5 to +30. The primary endpoint was cumulative incidence of grade 2–4 acute GVHD by day +100. All outcomes were based on intention-to-treat analysis. RESULTS: Forty-three patients were enrolled; median age was 19 years, with 74% receiving HLA-matched and 26% haploidentical HCT. The recommended phase II dose was 60 mg/m 2 twice daily. No dose-limiting toxicities, unexpected vorinostat-related serious adverse events, or primary graft failures occurred. Median neutrophil and platelet recovery occurred at 14 and 18 days, respectively. Day +100 grade 2–4 and 3–4 acute GVHD were 14% (95% CI, 5.6%–26%) and 4.7% (95% CI, 0.83%–14%), respectively. One-year overall survival was 88.4% (95% CI, 79.3%–98.5%), relapse 14% (95% CI, 5.6%–26%), nonrelapse mortality 4.7% (95% CI, 0.8%–14%), and GVHD-free/relapse-free survival 55.8% (95% CI, 42.8%–72.8%). Correlative studies demonstrated on-target HDAC activity, with increased histone. RESULTS: Forty-three patients were enrolled; median age was 19 years, with 74% receiving HLA-matched and 26% haploidentical HCT. The recommended phase II dose was 60 mg/m 2 twice daily. No dose-limiting toxicities, unexpected vorinostat-related serious adverse events, or primary graft failures occurred. Median neutrophil and platelet recovery occurred at 14 and 18 acetylation and lower proinflammatory cytokines. CONCLUSION: These findings support randomized evaluation of vorinostat-based GVHD prophylaxis in pediatric and AYA HCT. TRIAL REGISTRY: ClinicalTrials.gov NCT03842696. FUNDING: NIH grants 1R01CA249211, UG1HL069330, 1K24HL156896, and NHLBI Training Grant T32HL007622-36.
- Open Access
- 24 March 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (5) , 1000-1012
MHC class I on target cells regulates CD4+ T cell-mediated immunity
Major histocompatibility complex (MHC) class I and class II molecules present antigens to CD8 + and CD4 + T cells respectively. Here we uncover a previously unrecognized role for MHC class I in modulating CD4 + T cell-mediated immunity. In allogeneic graft-versus-host disease and tumor models, we demonstrate that the absence of MHC class I on target cells significantly increases their susceptibility to CD4 + T cell cytotoxicity. Transcriptomic and functional studies suggest that this was because of heightened sensitivity to enhanced ferroptosis of the target cells. In large human transcriptomic and sequencing datasets, a role for CD4 + T cells in enhancing immune checkpoint blocker-mediated responses in persons with melanoma and mismatch-repair-deficient colon cancers that have downregulated MHC class I was suggested. These findings revise and expand the known role of MHC class I in CD8 + T cell and natural killer cell immunity and demonstrate a previously unrecognized role in CD4 + T cell-mediated cancer and alloimmunity.
- 24 March 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (5) , 1000-1012
Open AccessMHC class I on target cells regulates CD4+ T cell-mediated immunity
Major histocompatibility complex (MHC) class I and class II molecules present antigens to CD8 + and CD4 + T cells respectively. Here we uncover a previously unrecognized role for MHC class I in modulating CD4 + T cell-mediated immunity. In allogeneic graft-versus-host disease and tumor models, we demonstrate that the absence of MHC class I on target cells significantly increases their susceptibility to CD4 + T cell cytotoxicity. Transcriptomic and functional studies suggest that this was because of heightened sensitivity to enhanced ferroptosis of the target cells. In large human transcriptomic and sequencing datasets, a role for CD4 + T cells in enhancing immune checkpoint blocker-mediated responses in persons with melanoma and mismatch-repair-deficient colon cancers that have downregulated MHC class I was suggested. These findings revise and expand the known role of MHC class I in CD8 + T cell and natural killer cell immunity and demonstrate a previously unrecognized role in CD4 + T cell-mediated cancer and alloimmunity.
- Open Access
- 23 October 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (24)
Mitochondrial complex II orchestrates divergent effects in CD4+ and CD8+ T cells
Mitochondrial metabolism orchestrates T cell functions, yet the role of specific mitochondrial components in distinct T cell subsets remains poorly understood. Here, we explored the role of mitochondrial complex II (MC II), the only complex from the electron transport chain (ETC) that plays a role in both ETC and metabolism, in regulating T cell functions. Surprisingly, MC II exerts divergent effects on CD4 + and CD8 + T cell activation and function. Using T cell–specific MC II subunit, succinate dehydrogenase A–deficient (SDHA-deficient) mice, we integrated single-cell RNA-seq and metabolic profiling, with in vitro and in vivo T cell functional assays to illuminate these differences. SDHA deficiency induced metabolic changes and remodeled gene expression exclusively in activated T cells. In CD4 + T cells, SDHA loss dampened both oxidative phosphorylation (OXPHOS) and glycolysis, impaired cytokine production, proliferation, and reduced CD4 + T cell–mediated graft-versus-host disease after allogeneic stem cell transplantation (SCT). In contrast, SDHA deficiency in CD8 + T cells reduced OXPHOS but paradoxically upregulated glycolysis and demonstrated enhanced cytotoxic functions in vitro and in vivo. This metabolic reprogramming endowed SDHA-KO CD8 + T cells with superior in vivo antitumor efficacy after immune checkpoint inhibitor therapy and allogeneic SCT. These findings reveal MC II as a bifurcation point for metabolic and functional specialization in CD4 + and CD8 + T cells.
- 23 October 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (24)
Open AccessMitochondrial complex II orchestrates divergent effects in CD4+ and CD8+ T cells
Mitochondrial metabolism orchestrates T cell functions, yet the role of specific mitochondrial components in distinct T cell subsets remains poorly understood. Here, we explored the role of mitochondrial complex II (MC II), the only complex from the electron transport chain (ETC) that plays a role in both ETC and metabolism, in regulating T cell functions. Surprisingly, MC II exerts divergent effects on CD4 + and CD8 + T cell activation and function. Using T cell–specific MC II subunit, succinate dehydrogenase A–deficient (SDHA-deficient) mice, we integrated single-cell RNA-seq and metabolic profiling, with in vitro and in vivo T cell functional assays to illuminate these differences. SDHA deficiency induced metabolic changes and remodeled gene expression exclusively in activated T cells. In CD4 + T cells, SDHA loss dampened both oxidative phosphorylation (OXPHOS) and glycolysis, impaired cytokine production, proliferation, and reduced CD4 + T cell–mediated graft-versus-host disease after allogeneic stem cell transplantation (SCT). In contrast, SDHA deficiency in CD8 + T cells reduced OXPHOS but paradoxically upregulated glycolysis and demonstrated enhanced cytotoxic functions in vitro and in vivo. This metabolic reprogramming endowed SDHA-KO CD8 + T cells with superior in vivo antitumor efficacy after immune checkpoint inhibitor therapy and allogeneic SCT. These findings reveal MC II as a bifurcation point for metabolic and functional specialization in CD4 + and CD8 + T cells.
- 11 September 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (11) , 1265-1275
Inflammatory memory of stem cells: implications for hematologic diseases
Immunological memory in adaptive and innate immune cells is well characterized, enabling enhanced responses upon secondary challenges. However, it has only been recently appreciated that the nonimmune target cells of inflammation, particularly organ-specific stem cells (SCs), also exhibit memory of previous inflammatory exposures. Previous inflammation experience imprints on the SCs and influences their regenerative potential and responses to subsequent inflammatory insults. This phenomenon has been observed in hematopoietic, intestinal, and skin epithelial SCs, with profound implications for tissue homeostasis, disease progression, and therapeutic strategies. Herein, we expand and develop the notion of inflammatory memory of SCs and explore recent insights in the field. We discuss the emerging understanding of the molecular underpinnings and their potential clinical and biological implications. Inflammatory memory is driven by spatiotemporal changes in gene loci and transcription regulated by DNA and histones’ epigenetic modifications, metabolic reprogramming, and chromatin accessibility changes. Understanding these mechanisms is critical for improving the outcomes of hematologic diseases, hematopoietic SC transplantation, and cellular immunotherapies.
- 11 September 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (11) , 1265-1275
Inflammatory memory of stem cells: implications for hematologic diseases
Immunological memory in adaptive and innate immune cells is well characterized, enabling enhanced responses upon secondary challenges. However, it has only been recently appreciated that the nonimmune target cells of inflammation, particularly organ-specific stem cells (SCs), also exhibit memory of previous inflammatory exposures. Previous inflammation experience imprints on the SCs and influences their regenerative potential and responses to subsequent inflammatory insults. This phenomenon has been observed in hematopoietic, intestinal, and skin epithelial SCs, with profound implications for tissue homeostasis, disease progression, and therapeutic strategies. Herein, we expand and develop the notion of inflammatory memory of SCs and explore recent insights in the field. We discuss the emerging understanding of the molecular underpinnings and their potential clinical and biological implications. Inflammatory memory is driven by spatiotemporal changes in gene loci and transcription regulated by DNA and histones’ epigenetic modifications, metabolic reprogramming, and chromatin accessibility changes. Understanding these mechanisms is critical for improving the outcomes of hematologic diseases, hematopoietic SC transplantation, and cellular immunotherapies.
- Open Access
- 2 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (17)
Corrigendum to Autophagy differentially regulates tissue tolerance of distinct target organs in graft-versus-host disease models
- 2 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (17)
Open AccessCorrigendum to Autophagy differentially regulates tissue tolerance of distinct target organs in graft-versus-host disease models
- Open Access
- 12 August 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (15) , 3878-3886
PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome
Relapse of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains the primary source of mortality after allogeneic hematopoietic stem cell transplantation (HCT). Targeting programmed death-1 (PD-1) for reversing T-cell exhaustion and restoring the graft-versus-leukemia (GVL) effect may have logistical advantages over donor lymphocyte infusion. In a prospective phase 1B clinical trial, pembrolizumab was administered every 3 weeks to 16 patients with AML (n = 12) and MDS (n = 4) in relapse after HCT to assess graft-versus-host disease (GVHD), clinical response, and survival. The median time to relapse after HCT was 5.5 months and the median pretreatment bone marrow blast percentage was 21.5%. The overall response rate was 31.3% for patients receiving pembrolizumab, consisting of 3 complete remissions (18.8%) and 2 partial remissions (13.5%). The median duration of response was 610 days. A significantly greater proportion of patients with mixed CD3 chimerism had a clinical response than those with full donor chimerism (50% vs 0%; P = .03). Immune toxicities were frequent, with 37.5% of patients developing severe (grade 3-4) GVHD after pembrolizumab, of which most had resistance to corticosteroids and contributed to death in 4 patients (25%). The 1-year overall survival (OS) was 37.5% and event-free survival was 31.3%. For AML, 1-year OS was 50.0%. In this trial, PD-1 inhibition led to durable remission in one-third of the patients experiencing early relapse after HCT, suggesting that this approach may augment the GVL response. Responses were exclusively observed in the setting of mixed CD3 donor chimerism. Immune toxicities (GVHD) were a barrier to successful treatment outcome. This trial was registered at www.ClinicalTrials.gov as #NCT03286114.
- 12 August 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (15) , 3878-3886
Open AccessPD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome
Relapse of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains the primary source of mortality after allogeneic hematopoietic stem cell transplantation (HCT). Targeting programmed death-1 (PD-1) for reversing T-cell exhaustion and restoring the graft-versus-leukemia (GVL) effect may have logistical advantages over donor lymphocyte infusion. In a prospective phase 1B clinical trial, pembrolizumab was administered every 3 weeks to 16 patients with AML (n = 12) and MDS (n = 4) in relapse after HCT to assess graft-versus-host disease (GVHD), clinical response, and survival. The median time to relapse after HCT was 5.5 months and the median pretreatment bone marrow blast percentage was 21.5%. The overall response rate was 31.3% for patients receiving pembrolizumab, consisting of 3 complete remissions (18.8%) and 2 partial remissions (13.5%). The median duration of response was 610 days. A significantly greater proportion of patients with mixed CD3 chimerism had a clinical response than those with full donor chimerism (50% vs 0%; P = .03). Immune toxicities were frequent, with 37.5% of patients developing severe (grade 3-4) GVHD after pembrolizumab, of which most had resistance to corticosteroids and contributed to death in 4 patients (25%). The 1-year overall survival (OS) was 37.5% and event-free survival was 31.3%. For AML, 1-year OS was 50.0%. In this trial, PD-1 inhibition led to durable remission in one-third of the patients experiencing early relapse after HCT, suggesting that this approach may augment the GVL response. Responses were exclusively observed in the setting of mixed CD3 donor chimerism. Immune toxicities (GVHD) were a barrier to successful treatment outcome. This trial was registered at www.ClinicalTrials.gov as #NCT03286114.
- 5 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (23) , 2774-2787
Novel regulators of GVHD revealed through microbiome and metabolome patterns across distinct intestinal regions
Microbial dysbiosis and metabolite changes in the gastrointestinal (GI) tract have been linked to pathogenesis and severity of many diseases, including graft-versus-host disease (GVHD), the major complication of allogeneic hematopoietic stem cell transplantation. However, published studies have only considered the microbiome and metabolome of excreted stool and do not provide insight into the variability of the microbial community and metabolite composition throughout the GI tract or the unique temporal dynamics associated with different gut locations. Because such geographical variations are known to influence disease processes, we used a multi-omics approach to characterize the microbiome and metabolite profiles of gut contents from different intestinal regions in well-characterized mouse models of GVHD. Our analysis validated analyses from excreted stool, but importantly, uncovered new biological insights from the microbial and metabolite changes between syngeneic and allogeneic hosts that varied by GI location and time after transplantation. Our integrated analysis confirmed the involvement of known metabolic pathways, including short-chain fatty acid synthesis and bile acid metabolism, and identified additional functional genes, pathways, and metabolites, such as amino acids, fatty acids, and sphingolipids, linked to GI GVHD. Finally, we validated a biological relevance for one such newly identified microbial metabolite, phenyl lactate, that heretofore had not been linked to GI GVHD. Thus, our analysis of the geographic variability in the intestinal microbiome and metabolome offers new insights into GI GVHD pathogenesis and potential for novel therapeutics.
- 5 June 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (23) , 2774-2787
Novel regulators of GVHD revealed through microbiome and metabolome patterns across distinct intestinal regions
Microbial dysbiosis and metabolite changes in the gastrointestinal (GI) tract have been linked to pathogenesis and severity of many diseases, including graft-versus-host disease (GVHD), the major complication of allogeneic hematopoietic stem cell transplantation. However, published studies have only considered the microbiome and metabolome of excreted stool and do not provide insight into the variability of the microbial community and metabolite composition throughout the GI tract or the unique temporal dynamics associated with different gut locations. Because such geographical variations are known to influence disease processes, we used a multi-omics approach to characterize the microbiome and metabolite profiles of gut contents from different intestinal regions in well-characterized mouse models of GVHD. Our analysis validated analyses from excreted stool, but importantly, uncovered new biological insights from the microbial and metabolite changes between syngeneic and allogeneic hosts that varied by GI location and time after transplantation. Our integrated analysis confirmed the involvement of known metabolic pathways, including short-chain fatty acid synthesis and bile acid metabolism, and identified additional functional genes, pathways, and metabolites, such as amino acids, fatty acids, and sphingolipids, linked to GI GVHD. Finally, we validated a biological relevance for one such newly identified microbial metabolite, phenyl lactate, that heretofore had not been linked to GI GVHD. Thus, our analysis of the geographic variability in the intestinal microbiome and metabolome offers new insights into GI GVHD pathogenesis and potential for novel therapeutics.
- Open Access
- 3 September 2024
- Published by Elsevier in Cell Stem Cell
- Vol. 31 (10) , 1447-1464.e6
Inflammation-induced epigenetic imprinting regulates intestinal stem cells
- 3 September 2024
- Published by Elsevier in Cell Stem Cell
- Vol. 31 (10) , 1447-1464.e6
Open AccessInflammation-induced epigenetic imprinting regulates intestinal stem cells